The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a stellar 70% rise in just two trading days, after the company announced positive data from early clinical trials for NTLA-2001, an experimental treatment for...
The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a stellar 70% rise in just two trading days, after the company announced positive data from early clinical trials for NTLA-2001, an experimental treatment for...
Share this Article
Recommended